Briacell Other Operating Expenses from 2010 to 2024
| BCTX Stock | USD 0.84 0.09 12.00% |
Other Operating Expenses | First Reported 2006-07-31 | Previous Quarter 9.1 M | Current Value 5.8 M | Quarterly Volatility 2.3 M |
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 86.7 K, Interest Expense of 0.0 or Other Operating Expenses of 34.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
Briacell | Other Operating Expenses |
Latest Briacell Therapeutics' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Briacell Therapeutics Corp over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Briacell Therapeutics. It is also known as Briacell Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Briacell Therapeutics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Briacell Other Operating Expenses Regression Statistics
| Arithmetic Mean | 6,981,966 | |
| Geometric Mean | 1,062,968 | |
| Coefficient Of Variation | 175.55 | |
| Mean Deviation | 9,277,734 | |
| Median | 1,384,556 | |
| Standard Deviation | 12,256,811 | |
| Sample Variance | 150.2T | |
| Range | 34.4M | |
| R-Value | 0.72 | |
| Mean Square Error | 78.2T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 1,970,248 | |
| Total Sum of Squares | 2103.2T |
Briacell Other Operating Expenses History
About Briacell Therapeutics Financial Statements
Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' Other Operating Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 32.8 M | 34.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.